For some tick-borne diseases, treatment guidelines are well established for successful outcome. For others, recommended treatment guidelines are varied, disputed, or even non-existent.
The CDC provides the Tick-borne Diseases of the United States: A Reference Manual for Health Care Providers to aid in diagnosis and treatment of tick-borne diseases.
Currently, the only NGC endorsed treatment guidelines specific to Lyme disease in the U.S. are peer-reviewed Evidence Assessments and Guideline Recommendations created in 2014 by ILADS (International Lyme and Associated Diseases Society).
The National Guidelines Clearinghouse (NGC) removed the IDSA (Infectious Disease Society of America) Lyme Treatment Guidelines (in February, 2016) because the guidelines were out of date.
The NGC’s official statement:
“It was removed from the NGC database because the guideline no longer met the NGC Inclusion Criteria pertaining to date. More specifically, the NGC inclusion criteria require that all guidelines represented in the NGC database have been developed, reviewed or revised within the last five years. All guidelines that no longer meet these criteria are removed from the NGC site on an annual basis.”
The CDC still endorses IDSA Lyme Treatment Guidelines on their webpage and does not endorse the ILADS guidelines.
ILADS offers an annotated appendix with comparisons of the IDSA and ILADS guidelines for both patient and physician review.
Both medical care providers and patients have a right to know that there are differing professional opinions in regard to the treatment of Lyme disease and other tick-borne infections. Awareness is critical for advocating for quality of life and health for yourself, your family or your patients!